National position statement for the management of latent tuberculosis infection

Commun Dis Intell Q Rep. 2017 Sep 1;41(3):E204-E208.

Abstract

The primary role of any tuberculosis (TB) control program is to ensure the prompt identification and effective treatment of active disease. The host immune system often succeeds in containing the initial (or primary) infection with Mycobacterium tuberculosis (Mtb), but may fail to eliminate the pathogen. The persistence of viable organisms explains the potential for the development of active disease years or even decades after infection. This is known as latent tuberculosis infection (LTBI) although, rather than a distinct entity, this probably represents part of a dynamic spectrum. Individuals with LTBI are asymptomatic and it is therefore clinically undetectable. The World Health Organization (WHO) estimates that one-third of the global population has been infected with Mtb, with highest prevalence of LTBI in countries/regions with the highest prevalence of active disease. In 2013, 88% of 1322 notifications in Australia were in the overseas-born population (incidence 19.5 per 100,000 v. 1.0 per 100,000), with this proportion rising over the course of the last decade. Combined with epidemiological evidence of low local transmission, this strongly implies that the vast majority resulted from reactivation of latent infection acquired prior to immigration. Contrasting trends in TB incidence in other developed countries probably reflect differences in policy regarding LTBI.

Conclusion: The diagnosis and treatment of LTBI represents an important opportunity for intervention by jurisdictional TB control programs.

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Australia / epidemiology
  • Chemoprevention / methods*
  • Communicable Disease Control / methods*
  • Disease Notification / statistics & numerical data
  • Drug Combinations
  • Emigration and Immigration / statistics & numerical data
  • Humans
  • Interferon-gamma Release Tests / statistics & numerical data
  • Isoniazid / therapeutic use
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy*
  • Latent Tuberculosis / epidemiology
  • Latent Tuberculosis / prevention & control
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / isolation & purification
  • Prevalence
  • Rifampin / analogs & derivatives
  • Rifampin / therapeutic use
  • Transients and Migrants / statistics & numerical data
  • Tuberculin Test / statistics & numerical data
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / epidemiology
  • Tuberculosis, Pulmonary / prevention & control

Substances

  • Antitubercular Agents
  • Drug Combinations
  • Isoniazid
  • Rifampin
  • rifapentine